Vivid Microscopy, an emerging biotech company in the United States, today announced the successful use of its high content screening probe, SEMKUR-IM, in a study conducted by the University of Louisville on coronary microvascular disease (CMD) in post-menopausal women.
A disease impacting over 3 million women yearly, microvascular dysfunction often presents with chest pain and shortness of breath, which can lead to heart failure. The current method of detection is through an angiogram or a specialized form of ultrasound. Early detection of the microvascular dysregulation signal is critical—if left undetected, it can lead to heart failure or a massive heart attack.
In experiments by the University of Louisville published in Antioxidant & Redox Signaling, scientists looked at four different conditions of cells and used various indicators to assess each state. Vivid’s probe was unique in that it could detect all stages of CMD (with minimal standard deviation) impacting blood supply to the heart. Using fluorescent technology, the SEMKUR-IM tool was able to differentiate the severity of the condition from initial stages to the most extreme, as well as assess the effectiveness of drugs targeted to treat the condition.